China SXT PharmaceuticalsSTU:2RY1 26 Quick Ratio is 4.24 as of Sep. 2025, which is 190% above its 10-year median of 1.46. GuruFocus rates STU:2RY1 with a GF Score™ of 26/100. The stock has 5 warning signs investors should review. Among 994 Drug Manufacturers companies, China SXT Pharmaceuticals ranks better than 85.71% on this metric.
China SXT Pharmaceuticals has a quick ratio of 4.24. It generally indicates good short-term financial strength.
The historical rank and industry rank for China SXT Pharmaceuticals's Quick Ratio or its related term are showing as below:
STU:2RY1'
s Quick Ratio Range Over the Past 10 Years
Min: 1.11 Med: 1.46 Max: 4.24
Current: 4.24
During the past 9 years, China SXT Pharmaceuticals's highest Quick Ratio was 4.24. The lowest was 1.11. And the median was 1.46.
STU:2RY1's Quick Ratio is ranked better than 85.71% of 994
companies
in the Drug Manufacturers industry
Industry Median: 1.45
vs STU:2RY1: 4.24
China SXT Pharmaceuticals (STU:2RY1) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
China SXT Pharmaceuticals Quick Ratio Related Terms
China SXT Pharmaceuticals Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:2RY1 vs CABR, BFRI, BIOE: Quick Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, China SXT Pharmaceuticals's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China SXT Pharmaceuticals Quick Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, China SXT Pharmaceuticals's Quick Ratio distribution charts can be found below:
* The bar in red indicates where China SXT Pharmaceuticals's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
China SXT Pharmaceuticals's Quick Ratio for the fiscal year that ended in Mar. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China SXT Pharmaceuticals (STU:2RY1) has a Quick Ratio of 4.24 as of Sep. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on China SXT Pharmaceuticals and its competitors. This is 190% above median its historical median of 1.46. Over the past decade, China SXT Pharmaceuticals' Quick Ratio has ranged from 1.11 to 4.24. According to the industry distribution chart, China SXT Pharmaceuticals ranks #142 out of 994 companies in the Drug Manufacturers industry, placing it in the top 14.3%.
Is China SXT Pharmaceuticals' Quick Ratio too high?
China SXT Pharmaceuticals' current Quick Ratio of 4.24 is 190% above median its 10-year median of 1.46. Over the past 10 years, this metric has ranged from a low of 1.11 to a high of 4.24. The Drug Manufacturers industry median Quick Ratio is 1.45. China SXT Pharmaceuticals' value of 4.24 is 192.4% above this industry median. Based on the distribution chart, China SXT Pharmaceuticals ranks #142 out of 994 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, China SXT Pharmaceuticals has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does China SXT Pharmaceuticals' Quick Ratio compare to CABR and BFRI?
According to the Drug Manufacturers industry distribution chart, China SXT Pharmaceuticals ranks #142 out of 994 companies for Quick Ratio. This places China SXT Pharmaceuticals in the top 14% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 1.45. China SXT Pharmaceuticals' value of 4.24 is 192.4% above this benchmark. Historically, China SXT Pharmaceuticals' own Quick Ratio has ranged from 1.11 to 4.24 over the past decade. While the company's 10-year median is 1.46 vs. the industry median of 1.45, China SXT Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Drug Manufacturers company?
The median Quick Ratio among Drug Manufacturers companies is 1.45, based on 994 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China SXT Pharmaceuticals's current Quick Ratio of 4.24 is 192.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on China SXT Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Quick Ratio is 1.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China SXT Pharmaceuticals's current Quick Ratio is 4.24, which is 190% above median its own 10-year median of 1.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China SXT Pharmaceuticals stock overvalued right now?
China SXT Pharmaceuticals (STU:2RY1) has a current Quick Ratio of 4.24. The current Quick Ratio is 4.24, which is 190% above median its 10-year median of 1.46 and 192.4% above the Drug Manufacturers industry median of 1.45. China SXT Pharmaceuticals' overall GF Score™ is 26/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For China SXT Pharmaceuticals (STU:2RY1), the current Quick Ratio is 4.24 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
China SXT Pharmaceuticals Inc is a pharmaceutical company that is focused on the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), particularly, TCMP (Directed-oral TCMP, and After-soaking TCMP) which is a sort of Traditional Chinese Medicine (TCM) that has been processed to be ready for use without decoction. Geographically, the firm generates its revenue from the People's Republic of China.
26GF Score
Get the complete analysis for STU:2RY1
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:2RY1 has been successfully added to your 
